Background: Despite introduction of improved immunosuppressants, treatment of JSLE remains challenging. As dysregulation of B cells is the hallmark of JSLE, clinical research has been focused on B-cell targeted therapies. Rituximab is a B cell depletion therapy directed against the CD20 receptor and studies, in JSLE, have shown improvement of the disease with few adverse events 1 . Metabolomics is involved in identifying and quantifying the biochemical by-products of metabolism. Variations in metabolite concentrations can serve as diagnostic or prognostic biomarkers. Metabolomic analysis in autoimmune diseases has shown that an improved disease score after treatment does not mean that the patient's immune system is corrected to that of healthy controls' 2 . Observing the metabolite prolife of sera from JSLE patients treated with/without Rituximab could provide an objective method to evaluate the effect of treatment. Aims: To compare the metabolite profile of sera of JSLE patients with and without Rituximab treatment to that of paediatric healthy controls. Methods: Serum samples were obtained from children (diagnosed <17 years) with JSLE who either received standard treatment (JSLEÀR, n ¼ 8) or standard treatment plus Rituximab (JSLEþR, n ¼ 3) within the last year and from paediatric healthy controls (n ¼ 9). The samples were run at 310 K on a Bruker 600 MHz AvanceIII with CryoProbe. Resulting 1 H NMR spectra were analysed with Topspin and Chenomx NMR Suite. Results: Global changes in spectra analysed via Principal Component Analysis (PCA) revealed that JSLEþR patients did not exhibit a distinct profile. However one-way ANOVA showed that specific metabolites including Lysine (Fig. 1) were significantly higher (p < 0.05) in JSLEÀR patients compared to healthy controls, and that these levels were lowered to control levels in JSLEþR patients. The proteolipid profiles in JSLE-R sera was similar to controls, but was significantly higher in JSLE+R patients compared to both other groups (Fig. 2) . Conclusions: Variation in metabolic profiles was observed in those patients receiving Rituximab treatment. While many metabolite levels were not affected by Rituximab treatment compared to healthy control or patients not receiving Rituximab treatment, some metabolites varied with diagnosis and treatment. This small study indicates that the effects of Rituximab treatment can be observed in the metabolite levels found in JSLE sera and therefore the environment of immune cells needs further monitoring.
Background: The incidence of Juvenile-onset Systemic Lupus Erythematosus (JSLE) in the UK is unknown. Furthermore we do not know how children and young people initially present and when and where they access care. New European (SHARE guidelines) are soon to be published, providing recommendations on how children and young people with suspected JSLE should be managed 1 . A study determining the incidence of JSLE and providing insight into where we look after children and young people with JSLE in the UK and Ireland is urgently needed. Aims: To develop robust methodology to determine the incidence of JSLE in children and young people, and explore their access to care within the UK and Ireland. Methods: We applied to the British Paediatric Surveillance Unit (BPSU) to run the study through their well-established, and robust methodology of rare disease epidemiology 2 . In addition, we approached relevant groups of clinicians across the UK to identify 5. Figure 1 . Analysing peak intensity after Pareto-scaling and normalisation to median. While the JSLEÀR group was significantly increased in Lysine (p ¼ 0.003), it was in healthy range in JSLEþR patients.
5. Figure 2 . Analysing peak intensity after Pareto-scaling and normalisation to median. The JSLEþR group showed a significant higher amount of polyunsaturated fatty acids (p ¼ 0.002) compared to the Control and JSLEÀR group.
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